Bristol-Myers CEO's 2009 compensation down 22 pct
10.03.10
TRENTON, N.J. — The chief executive of drugmaker Bristol-Myers Squibb Co., James Cornelius, received a 2009 compensation package valued by The Associated Press at $17 million, down 22 percent from 2008, due to the much lower value of his stock awards.
The maker of blood thinner Plavix, schizophrenia treatment Abilify and HIV drugs Reyataz and Sustiva gave Cornelius a salary of $1.5 million, up just $12,000 from the year before.
The company announced last week that Cornelius is retiring on May 4 after 3 1/2 years at the helm.
His performance bonus edged up to $4.49 million from $4.48 million in 2008, according to a proxy statement filed Tuesday with the Securities and Exchange Commission.
Most of his compensation comes from long-term awards of stock options and restricted shares. That total fell 31 percent to $10.9 million in 2009, from $15.7 million in 2008.
Cornelius's other compensation — all for use of a car — totaled $68,863.
Source: The Associated Press
Anti-hypertension - Drug Pipeline Analysis and Market Forecasts to 2016
26.02.10
GlobalData found that the current competition in the anti-hypertension market is very strong. The market in 2009 was dominated by ARBs such as Diovan, Atacand, Blopress and Avapro. In 2009, agents acting on the renin angiotensin system dominated the anti-hypertension market and they accounted for approximately 60% of the market. ARBs alone accounted for 42.6% of the global anti-hypertension market. Among the drugs approved for hypertension, diuretics are the most cost effective drugs. Despite the cost effectiveness and efficacy of diuretics, ARBs and Angiontensin converting enzyme (ACE) inhibitors are the most widely prescribed antihypertensive therapies in the market. In 2009, they accounted for approximately 30% to 40% of the global hypertension prescription volume. BBs were the second leading therapeutic class of drugs, accounting for approximately 30% of the global hypertension prescription volume. Diuretics were the third leading therapeutic class of drugs accounting for approximately
Source: Jazzou (blog)
Dainippon Sumitomo Pharma Co., Ltd. Second Mid-term Business Plan
15.02.10
Dainippon Sumitomo Pharma Co., Ltd. (the "Company") announces that it has formulated the second Mid-term Business Plan (the "MTBP") for the five years beginning with fiscal 2010.
The Mid to Long term Vision (the "Vision") that the Company drew up in 2007 set the targets of "Establish a solid foundation for our domestic business," "Expand our international business operation" and "Enrich our R&D product pipeline to realize our future vision" in envisioning its corporate status for the next ten years. For its vision of the next 15 years, the Company aims to become an internationally competitive R&D-oriented pharmaceutical company and to have two solid mainstreams of revenue, from domestic operations and from international operations.
In the three-year first MTBP ending with fiscal 2009, the Company worked to upgrade and strengthen its business platform for globalization and submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ahead of schedule for lurasidone, an investigational agent for schizophrenia being developed globally. In addition, the Company progressed significantly in its globalization by establishing and expanding its business platform and R&D facilities in North America through the acquisition of Sepracor Inc. ("Sepracor").
Source: Asahi Shimbun
The company will also lose patent protection on hypertension treatment Avapro that year. Together, the two drugs made up nearly 40% of the company's net
more than 7000 people worldwide, markets a number of medications, including an antipsychotic called Lonasen and the hypertension medication Avapro.